Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial
Main Article Content
Keywords
TYK2, deucravacitinib, plaque psoriasis
Abstract
Introduction: Tyrosine kinase 2 (TYK2) is an intracellular enzyme that mediates signaling of cytokines (eg, interleukin-23, Type I interferons) involved in psoriasis pathogenesis. Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. In POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751), deucravacitinib was significantly more effective vs placebo and apremilast based on multiple endpoints. This study compared efficacy of deucravacitinib vs apremilast over 24 weeks in mean Psoriasis Area and Severity Index (PASI) improvements and evaluated absolute PASI thresholds with continuous deucravacitinib treatment from Day 1 through 52 weeks in PSO-1.
Methods: PSO-1 randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily; patients randomized to placebo and apremilast switched to deucravacitinib at Week 16 and Week 24, respectively. Mean change from baseline in PASI and proportions of patients achieving absolute PASI thresholds of ≤1, ≤2, ≤3, ≤4, and ≤5 were evaluated at Week 24 (deucravacitinib vs apremilast) and Week 52 (deucravacitinib only).
Results: Mean baseline PASI was similar in both groups (deucravacitinib, 21.8; apremilast, 21.4). Significantly greater mean percent reductions from baseline in PASI were observed with deucravacitinib vs apremilast at Week 24 (−77.1% vs −50.2%; P < 0.0001); mean reduction in the deucravacitinib group was maintained through Week 52 (−78.4%). Higher proportions of patients receiving deucravacitinib vs apremilast, respectively, achieved absolute PASI thresholds of ≤1 (31.3% vs 12.5%), ≤2 (41.3% vs 21.4%), ≤3 (54.8% vs 28.0%), ≤4 (63.3% vs 33.3%), and ≤5 (68.7% vs 35.7%) at Week 24 (nominal P < 0.0001 for all); response rates were maintained through Week 52 with deucravacitinib (31.3%, 45.5%, 54.5%, 61.4%, and 66.0%, respectively).
Conclusions: Deucravacitinib treatment was associated with clinically meaningful PASI outcomes that were superior to apremilast over 24 weeks and maintained through 52 weeks in patients with moderate to severe plaque psoriasis.
References
2. Sotyktu [package insert]. Princeton, NJ: Bristol Myers Squibb; September 2022.
3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023.
4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022.
5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022.
6. Sotyktu [product monograph]. Montreal, QC, Canada: Bristol Myers Squibb Canada Co.; November 2022.
7. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.
8. Armstrong AW, et al. J Am Acad Dermatol. 2023;88:29-39.
9. Strober B, et al. J Am Acad Dermatol. 2023;88:40-51.
10. Lebwohl M, et al. Presented at the American Academy of Dermatology Annual Meeting; March 25-29, 2022; Boston, MA.
11. Puig L, et al. Acta Derm Venereol. 2019;99:971-977.
12. Mahil SK, et al. Br J Dermatol. 2020; 182:1158-1166.
13. Gisondi P, et al. Dermatol Ther (Heidelb). 2021;11:235-252.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.